The World Health Organization (WHO) criteria for MB diagnosis from 2021 categorizes them as grade IV malignant embryonal tumors and classifies them into SHH-activated TP53-wildtype, SHH-activated TP53-mutant, WNT-activated, and non-WNT/non-SHH subtypes [6]. This evidence concerns the gene SHH and embryonal neoplasm.